<DOC>
	<DOCNO>NCT00915512</DOCNO>
	<brief_summary>The purpose study evaluate response treatment safety paliperidone extended-release ( mechanism dissolve drug time order release slow steadier blood stream ) participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) .</brief_summary>
	<brief_title>A Phase 4 Study Evaluate Response Treatment Safety Paliperidone Extended-Release Participants With Schizophrenia</brief_title>
	<detailed_description>This non-randomized , single-arm , multi-center ( conducted one center ) study explore response treatment safety flexible dose paliperidone extended-release ( ER ) participant schizophrenia . During study period , dose paliperidone ER remain within range 3 12 milligram per day administer 12 month . Both hospitalize non-hospitalized participant may include study . Participants may switch effective dose paliperidone ER oral antipsychotic medication without dose adjustment require , cross-dose adjustment may do . Maximum 4 week switch period allow . Use anticholinergic ( oppose action acetylcholine , neurotransmitter ) drug restrict . Response treatment evaluate primarily total Personal Social Performance ( PSP ) Scale . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Schizophrenia diagnosis accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) Recent onset ( less 3 year first episode/hospitalization ) schizophrenia either antipsychotic medication least 3 month need antipsychotic medication switch safety and/or lack efficacy reason To consider physically healthy Screening accord vital sign physical examination finding . If abnormality , must consistent underlie illness study population Women postmenopausal state least 1 year ; undergone surgical sterilization , woman childbearing status , willing use effective contraceptive method throughout study Participants willing capable complete questionnaire Use clozapine , depot neuroleptic risperidone within last 3 month Any unstable clinical condition include clinically important abnormal laboratory finding Previous current tardive dyskinesia ( abnormal involuntary movement primarily affect extremity , trunk , jaw ) symptoms History malignant neuroleptic syndrome To consider carry high risk regard adverse effect , homicide and/or suicide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Invega</keyword>
</DOC>